Literature DB >> 16850005

Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients.

Minou Adib-Conquy1, Christophe Adrie, Catherine Fitting, Olivier Gattolliat, Rudi Beyaert, Jean-Marc Cavaillon.   

Abstract

OBJECTIVE: Immune status is altered during systemic inflammatory response syndrome and sepsis. Reduced ex vivo tumor necrosis factor production has been regularly reported with lipopolysaccharide-activated monocytes. In this study, we addressed the specificity of this hyporeactivity and investigated some of the possible associated mechanistic events.
DESIGN: Ex vivo study.
SETTING: Academic research laboratory. PATIENTS: Healthy controls, septic patients, and resuscitated patients after cardiac arrest (RCA). This latter group presents a systemic inflammatory response syndrome of noninfectious origin. INTERVENTION: None.
MEASUREMENTS AND MAIN RESULTS: We investigated the reactivity of patients' monocytes in terms of cytokine production, after stimulation with a Toll-like receptor (TLR) 2 (Pam3CysSK4), a TLR4 (lipopolysaccharide), a Nod2 agonist (muramyl dipeptide), or heat-killed bacteria. We also investigated the contribution of phagocytosis in cytokine production, studied the expression of intracellular bacterial peptidoglycan sensors (Nod1 and Nod2), and analyzed the messenger RNA expression of inhibitors of TLR signaling: Toll interacting protein (Tollip), suppressor of cytokine signaling-1 (SOCS1), myeloid differentiation 88 short (MyD88s), and single immunoglobulin interleukin-1 receptor-related molecule (SIGIRR). In sepsis, tumor necrosis factor production in response to lipopolysaccharide and Pam3CysSK4 was reduced, whereas interleukin-10 production was enhanced. The responsiveness to Staphylococcus aureus, Escherichia coli, and muramyl dipeptide and the expression of Nod1 and Nod2 were similar to those obtained for healthy donors. The messenger RNA expression of Tollip and SOCS1 was unchanged, whereas that of MyD88s and SIGIRR was significantly enhanced compared with healthy controls. Monocytes from RCA patients showed a reduced production of tumor necrosis factor in response to lipopolysaccharide but neither to Pam3CysSK4 nor to heat-killed bacteria. They displayed an increased expression of SIGIRR but not of MyD88s. We showed that TLR2-dependent nuclear factor-kappaB activation was inhibited by MyD88s but not by SIGIRR. This result may explain the normal tumor necrosis factor production through TLR2 observed for monocytes of RCA patients.
CONCLUSION: There is a "reprogramming" of monocyte reactivity, and not a global hyporeactivity, during systemic inflammation, which differs in septic and RCA patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16850005     DOI: 10.1097/01.CCM.0000233875.93866.88

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  47 in total

1.  Alternative pre-mRNA splicing of Toll-like receptor signaling components in peripheral blood mononuclear cells from patients with ARDS.

Authors:  Rachel Z Blumhagen; Brenna R Hedin; Kenneth C Malcolm; Ellen L Burnham; Marc Moss; Edward Abraham; Tristan J Huie; Jerry A Nick; Tasha E Fingerlin; Scott Alper
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Increased ratio of Th17 cells to SIGIRR+CD4+ T cells in peripheral blood of patients with SLE is associated with disease activity.

Authors:  Jian-Ping Xiao; Dao-Yang Wang; Xue-Rong Wang; Liang Yuan; Li Hao; De-Guang Wang
Journal:  Biomed Rep       Date:  2018-08-03

3.  SIGIRR inhibits toll-like receptor 4, 5, 9-mediated immune responses in human airway epithelial cells.

Authors:  Chun Zhang; Xueling Wu; Yunfeng Zhao; Zhaoxia Deng; Guisheng Qian
Journal:  Mol Biol Rep       Date:  2010-04-03       Impact factor: 2.316

4.  Altered Toll-like receptor 2-mediated endotoxin tolerance is related to diminished interferon beta production.

Authors:  Svetislav S Zaric; Wilson A Coulter; Charles E Shelburne; Catherine R Fulton; Marija S Zaric; Aaron Scott; Mark J Lappin; Denise C Fitzgerald; Christopher R Irwin; Clifford C Taggart
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

5.  Human endogenous retrovirus W family envelope protein (HERV-W env) facilitates the production of TNF-α and IL-10 by inhibiting MyD88s in glial cells.

Authors:  Xiuling Wang; Xiulin Wu; Jin Huang; Haiyan Li; Qiujin Yan; Fan Zhu
Journal:  Arch Virol       Date:  2021-01-12       Impact factor: 2.574

6.  Resilience to bacterial infection: difference between species could be due to proteins in serum.

Authors:  H Shaw Warren; Catherine Fitting; Eva Hoff; Minou Adib-Conquy; Laura Beasley-Topliffe; Brenda Tesini; Xueya Liang; Catherine Valentine; Judith Hellman; Douglas Hayden; Jean-Marc Cavaillon
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

7.  IRAK-M regulates chromatin remodeling in lung macrophages during experimental sepsis.

Authors:  Kenneth Lyn-Kew; Eric Rich; Xianying Zeng; Haitao Wen; Steven L Kunkel; Michael W Newstead; Urvashi Bhan; Theodore J Standiford
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

8.  Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation.

Authors:  Oh Yoen Kim; Antoine Monsel; Michèle Bertrand; Pierre Coriat; Jean-Marc Cavaillon; Minou Adib-Conquy
Journal:  Crit Care       Date:  2010-04-13       Impact factor: 9.097

9.  Comparative genomics RNAi screen identifies Eftud2 as a novel regulator of innate immunity.

Authors:  Lesly De Arras; Rebecca Laws; Sonia M Leach; Kyle Pontis; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  Genetics       Date:  2013-12-20       Impact factor: 4.562

10.  Effects of Lansoprazole on the Lipopolysaccharide-Stimulated Toll-Like Receptor 4 Signal Transduction Systems: A Study Using the 293hTLR4/MD2-CD14 Cells.

Authors:  Tadashi Ohara; Yuhsaku Kanoh; Keiichi Yoshino; Masaki Kitajima
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.